VC Roundup: 2Q Financings Fall As Per-Company Averages Rise

Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.

microscope

US venture capital investment in biotechnology companies fell during the second quarter, but remained near recent record-breaking levels as investors continued to support larger funding rounds for some biotechnology startups – a trend that's ongoing in the third quarter with Series A rounds totaling $57m for Oncorus Inc. and $55m for Fulcrum Therapeutics.

A hundred biotech companies raised $1.7bn during the second quarter of 2016 compared with 127 that raised $2.1bn during the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.